Will Zosyn (piperacillin‑tazobactam) kill Enterobacter?

Zosyn Activity Against Enterobacter: Context-Dependent with Important Caveats

Zosyn (piperacillin-tazobactam) can kill Enterobacter species that are susceptible to it, but this requires specific conditions: the organism must be third-generation cephalosporin-susceptible, extended infusion dosing should be used, and certain high-risk Enterobacter species should be avoided entirely.

Critical Species Distinctions

Not all Enterobacter are equal when considering Zosyn therapy:

• Avoid Zosyn for: Enterobacter cloacae, Citrobacter freundii, and Klebsiella aerogenes - these have moderate to high likelihood of clinically significant AmpC β-lactamase production, which can lead to treatment failure even with in-vitro susceptibility 1

• Never use for: Any Enterobacter that is third-generation cephalosporin-nonsusceptible (ceftriaxone or cefotaxime resistant), as this indicates AmpC production or ESBL production 1

When Zosyn May Be Appropriate

For third-generation cephalosporin-susceptible Enterobacter (excluding the high-risk species above):

• Zosyn is included in major guidelines for empiric therapy of critically ill patients with community-acquired intra-abdominal infections at 4.5 g every 6 hours 2
• Also recommended for healthcare-associated infections in non-critically ill patients 2

Dosing is critical: The susceptibility breakpoint is ≤16/4 mg/L, and only extended infusion regimens are endorsed (infused over 3-4 hours) 1. Standard intermittent infusions may fail even against susceptible isolates.

Evidence of Risk

The concern about Zosyn for Enterobacter is not theoretical:

• In immunocompromised patients with cefoxitin-nonsusceptible Enterobacterales (a marker of AmpC production), piperacillin/tazobactam showed significantly more microbiological failure (11.4% vs 0.0%) compared to cefepime/carbapenems 3

• Previous use of third-generation cephalosporins independently predicts Zosyn-resistant Enterobacter bacteremia 4

• Resistance can emerge during therapy at frequencies of 10⁻⁷ to 10⁻⁶, though tazobactam does suppress this somewhat 5

Preferred Alternatives

For confirmed or suspected AmpC-producing Enterobacter:

• First choice: Carbapenems (meropenem 1 g every 8 hours, imipenem 1 g every 8 hours, or ertapenem 1 g every 24 hours for less severe infections) 2, 6
• Alternative: Cefepime 2 g every 8 hours (though some controversy exists) 2, 6

For ESBL-producing Enterobacter:

• Carbapenems are strongly preferred 2
• Ertapenem 1 g every 24 hours for non-critically ill patients 2

Practical Algorithm

1. Identify the species: If E. cloacae, C. freundii, or K. aerogenes → avoid Zosyn, use carbapenem or cefepime

2. Check cephalosporin susceptibility: If ceftriaxone/cefotaxime resistant → avoid Zosyn, use carbapenem

3. If other Enterobacter species AND third-generation cephalosporin-susceptible:

   • Zosyn may be used at 4.5 g every 6 hours as extended infusion (over 3-4 hours)
   • Confirm MIC ≤16/4 mg/L if available
   • Monitor closely for clinical failure

4. Previous third-generation cephalosporin exposure? → Consider alternative to Zosyn due to increased resistance risk 4

Bottom Line

While the FDA label lists Enterobacter as covered by Zosyn 7, and one older study showed empiric Zosyn associated with lower mortality in Enterobacter bacteremia 8, current expert consensus strongly cautions against Zosyn for high-risk Enterobacter species and any third-generation cephalosporin-nonsusceptible strains 1. The mechanism involves AmpC β-lactamase that can be induced or derepressed during therapy, leading to treatment failure despite initial susceptibility.